| 4.7 -0.19 (-3.89%) | 12-08 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 6.37 | 1-year : | 7.08 |
| Resists | First : | 5.45 | Second : | 6.07 |
| Pivot price | 5.26 |
|||
| Supports | First : | 4.46 | Second : | 3.71 |
| MAs | MA(5) : | 4.96 |
MA(20) : | 5.16 |
| MA(100) : | 5.33 |
MA(250) : | 6.11 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 9.1 |
D(3) : | 21 |
| RSI | RSI(14): 41.7 |
|||
| 52-week | High : | 8.77 | Low : | 3.49 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MGTX ] has closed below the lower bollinger band by 3.3%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ MGTX ] is to continue within current trading range. Bollinger Bands are 14.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.98 - 5.03 | 5.03 - 5.06 |
| Low: | 4.53 - 4.59 | 4.59 - 4.63 |
| Close: | 4.63 - 4.73 | 4.73 - 4.79 |
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
Tue, 21 Nov 2023
MeiraGTx to Participate in Upcoming Investor Conferences - EIN News
Thu, 16 Nov 2023
MeiraGTx Holdings Third Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
Tue, 14 Nov 2023
MeiraGTx GAAP EPS of -$0.74, revenue of $5.1M (NASDAQ:MGTX) - Seeking Alpha
Tue, 14 Nov 2023
MeiraGTx Holdings PLC Reports Q3 2023 Financial Results and Operational Progress - Yahoo Finance
Mon, 30 Oct 2023
MeiraGTx shares take off on $30M investment by Sanofi - Proactive Investors UK
Mon, 30 Oct 2023
MeiraGTx Shares Jump 34% After Sanofi Investment - MarketWatch
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 64 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 4.8 (%) |
| Held by Institutions | 61 (%) |
| Shares Short | 1,640 (K) |
| Shares Short P.Month | 1,010 (K) |
| EPS | -2.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.53 |
| Profit Margin | 0 % |
| Operating Margin | -642.1 % |
| Return on Assets (ttm) | -29.6 % |
| Return on Equity (ttm) | -122.7 % |
| Qtrly Rev. Growth | 6 % |
| Gross Profit (p.s.) | 0.25 |
| Sales Per Share | 0.1 |
| EBITDA (p.s.) | -1.92 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -107 (M) |
| Levered Free Cash Flow | -57 (M) |
| PE Ratio | -1.89 |
| PEG Ratio | -0.9 |
| Price to Book value | 3.05 |
| Price to Sales | 44.68 |
| Price to Cash Flow | -2.8 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|